# ALLINAIRE THERAPEUTICS, LLC: An anti-EMAP II monoclonal antibody as a first-in-class treatment for Group III pulmonary hypertension patients with chronic obstructive pulmonary disease

**Lab Budget Score:** 70/100

| Field | Value |
|---|---|
| Organization | ALLINAIRE THERAPEUTICS, LLC |
| Location | CLEVELAND, OH |
| Project | An anti-EMAP II monoclonal antibody as a first-in-class treatment for Group III pulmonary hypertension patients with chronic obstructive pulmonary disease |
| Project number | 1R44HL186831-01 |
| Mechanism | R44 |
| Institute | National Heart Lung and Blood Institute |
| Award | $1,498,892 |
| Awarded | 2026-09-09 |
| Project period | 2026-09-05 to 2028-08-31 |
| UEI | K5GFMW6QF1P7 |

## Why this score
- Award of $1M or more.
- Research or center grant: supplies, instruments and services budget.

Source: NIH RePORTER (newly awarded projects) (https://reporter.nih.gov/project-details/11403849). Last refreshed: 2026-11-03T18:16:24.961Z.
Award data comes from NIH RePORTER and may be revised by NIH. Organization-level only; investigator names and contacts are not included. Informational only.